Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in EGFR FISH Positive NSCLC
NCT00796549Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2008
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Started Dec 2008; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00796549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796549.